ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1618

Intervention to Improve Medication Adherence Among Patients with SLE

Kai Sun1, Nneka Molokwu1, Emily Hanlen1, Amy Corneli2, Kathryn Pollak1, Jennifer Rogers1, Rebecca Sadun1, Lisa Criscione-Schreiber2, Jayanth Doss1, Hayden Bosworth1 and Megan Clowse3, 1Duke University, Durham, NC, 2Duke University School of Medicine, Durham, NC, 3Duke University, Chapel Hill, NC

Meeting: ACR Convergence 2023

Keywords: health behaviors, Health Services Research, Intervention, Qualitative Research, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 13, 2023

Title: Abstracts: Health Services Research II

Session Type: Abstract Session

Session Time: 2:00PM-3:30PM

Background/Purpose: Medication nonadherence is common and is associated with increased disease activity, morbidity, and mortality in SLE. To optimize medication adherence and SLE outcomes, we developed a simple clinician-led adherence intervention that involves clinicians reviewing real-time pharmacy refill data during the encounter and using effective communication techniques with patients to collaboratively overcome adherence barriers (Figure 1). Prior pilot testing demonstrated intervention feasibility, acceptability, and preliminary effect on adherence. In this study, we aimed to examine how the intervention is performed in practice and identify areas for improvement to inform future implementation.

Methods: We audio recorded clinic encounters between clinicians and patients seen at an academic lupus clinic. Patients were included if they had 90-day medication possession ratio (MPR) < 80% for SLE-specific medications. We coded which intervention components clinicians performed, quality of patient-clinician communication, and time spent discussing adherence. Following the intervention encounter, we also conducted audio-recorded semi-structured interviews with patients and clinicians about their experiences with the intervention and analyzed the data using applied thematic analysis. Lastly, we assessed change in 90-day MPR after the intervention visit and considered a 20% increase as major improvement.

Results: We recorded and analyzed 25 patient encounters (median age 39, 100% female, 72% Black) among 6 clinicians. Clinicians performed the majority of intervention components in most of encounters, suggesting fidelity (Table 1). Global communication scores and rates of active patient participation were high, suggesting excellent communication. Adherence discussions took on average 3.8 minutes.

Nineteen patients and 5 clinicians completed in-depth interviews. Nearly all participants felt the time spent discussing adherence was just right and necessary. Almost all patients felt the intervention was useful. Many patients described feeling heard and valued, being more honest about nonadherence, and being more knowledgeable and motivated to take SLE medications. Clinicians described less judgmental adherence discussions as a result of the intervention. To improve the intervention, patients emphasized better patient-clinician communication and wanted help problem solving financial and logistical barriers. Clinicians suggested additional resources and training to improve adherence conversations and utilizing peer support and other staff in the intervention.

Following the intervention visit, almost half (48%) of patients had a major improvement ( >20% increase) in MPR.

Conclusion: Our findings suggest that this intervention can be performed with high fidelity in a short amount of time. It encouraged high quality communication and improved adherence. Both patients and clinicians described positive experiences with the intervention. Future work will focus on optimizing clinician training, exploring ways to increase the intervention’s efficiency and effectiveness, and testing the intervention in a larger controlled setting.

Supporting image 1

Figure 1. Adherence intervention steps.

Supporting image 2

Table 1. Intervention components performed during 25 recordings of the adherence intervention.

Supporting image 3

Table 2. Quality of patient-clinician communication during the adherence intervention.


Disclosures: K. Sun: AstraZeneca, 6; N. Molokwu: None; E. Hanlen: None; A. Corneli: None; K. Pollak: None; J. Rogers: Amgen, 2, Ampel Biosolutions, 1, AstraZeneca, 6, Aurinia, 1, Eli Lilly, 1, Exagen, 5, GlaxoSmithKlein(GSK), 2, Immunovant, 2, 5; R. Sadun: None; L. Criscione-Schreiber: GlaxoSmithKlein(GSK), 5, UCB, 5; J. Doss: None; H. Bosworth: None; M. Clowse: Exagen, 5, GlaxoSmithKlein(GSK), 2, 5, Immunovant, 5, UCB, 2, 5.

To cite this abstract in AMA style:

Sun K, Molokwu N, Hanlen E, Corneli A, Pollak K, Rogers J, Sadun R, Criscione-Schreiber L, Doss J, Bosworth H, Clowse M. Intervention to Improve Medication Adherence Among Patients with SLE [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/intervention-to-improve-medication-adherence-among-patients-with-sle/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/intervention-to-improve-medication-adherence-among-patients-with-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology